CeriBell (NASDAQ:CBLL – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08), Zacks reports. The company had revenue of $18.53 million during the quarter, compared to analysts’ expectations of $17.55 million. CeriBell updated its FY 2025 guidance to EPS.
CeriBell Price Performance
CeriBell stock opened at $25.54 on Wednesday. The stock’s fifty day moving average price is $23.43. CeriBell has a 12-month low of $18.69 and a 12-month high of $32.75.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on CBLL shares. Canaccord Genuity Group lifted their price objective on CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 9th. William Blair initiated coverage on CeriBell in a research report on Tuesday, November 5th. They issued an “outperform” rating for the company. TD Cowen increased their price target on shares of CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. JPMorgan Chase & Co. started coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective for the company. Finally, Canaccord Genuity Group began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price target for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, CeriBell currently has an average rating of “Buy” and an average target price of $32.60.
About CeriBell
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Stories
- Five stocks we like better than CeriBell
- Using the MarketBeat Dividend Tax Calculator
- Twilio, Braze: The Top 2 CEP Platforms to Own in 2025
- Trading Stocks: RSI and Why it’s Useful
- Tempus AI Is a Buy, If You Can Handle the Volatility
- Industrial Products Stocks Investing
- Massive Buybacks: 3 Stocks Returning Big Cash to Shareholders
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
